PHIOGEN

PHIOGEN has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle chronic and life-threatening infections

[PHIOGEN @PHIOGEN]

We are thrilled to shared PHIOGEN has been awarded a $1.1 M grant from CARB-X to further develop our first-in-class dual-action therapeutics that treat and prevent recurrent infections!

[CARB-X @CARB_X]

@CARB_X has awarded @PHIOGEN US$1.1M to evaluate PHI-BI-01, its novel, dual-action therapeutic designed to treat and prevent ExPEC bloodstream infections, particularly those caused by multidrug-resistant strains.

🔗 Read here: https://t.co/rSzBt9xwiP

[PHIOGEN @PHIOGEN]

@CARB_X We are excited to join the CARB-X portfolio!

[CARB-X @CARB_X]

@CARB_X has awarded @PHIOGEN US$1.1M to evaluate PHI-BI-01, its novel, dual-action therapeutic designed to treat and prevent ExPEC bloodstream infections, particularly those caused by multidrug-resistant strains.

🔗 Read here: https://t.co/rSzBt9xwiP

[PHIOGEN @PHIOGEN]

Our team just applied to Startup World Cup @SWC2023 #CompanyName #StartupWorldCup @SWCPTV